RecruitingPhase 2NCT06951217
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Avalyn Pharma Inc.
- Principal Investigator
- Avalyn Pharma, Inc.Avalyn Pharma Inc.
- Intervention
- AP01(combination_product)
- Enrollment
- 340 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (30)
- University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States
- Renstar Medical Research, Ocala, Florida, United States
- Piedmont Healthcare, Inc., Atlanta, Georgia, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Hannibal Regional Healthcare System, Inc., Hannibal, Missouri, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Columbia University, New York, New York, United States
- Piedmont HealthCare, PA, Statesville, North Carolina, United States
- Southeastern Research Center, Winston-Salem, North Carolina, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- The University of Kansas Medical Center, Kansas, Ohio, United States
- Summit Health, Bend, Oregon, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Temple University Hospital, Philadelphia, Pennsylvania, United States
- Lowcountry Lung and Critical Care, PA, Charleston, South Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06951217 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics